Skip to main content
OpenTrials
Completed

NCT Number: NCT02101255

Effect of Curodont™ Repair in Patients With Early Approximal Carious Lesions

The purpose of this study is to evaluate the therapeutic benefit of Curodont Repair for the treatment of early approximal carious lesions compared to fluoride.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Zahnheilkunde Seifert Gmbh

Sirnach, Thurgau, 8370, Switzerland

About this study

All study participants must have two early approximal carious lesions in need of a treatment but not of an invasive treatment (split-mouth design). One lesion will be treated with Curodont Repair and one with fluoride as control. Study duration is 24 months. For assessment x-ray pictures, Diagnodent Pen and DiagnoCam is used.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Two approximal carious lesions on different teeth with at least one tooth in between
  • Both study lesions must not require an invasive treatment
  • Size and form of the lesions: the lesions must be fully visible and assessable on radiographs
  • The two carious lesions must fall into classes:
  • D2 (inner half of enamel)
  • D3 (outer part of dentine) but only if very little dentine is involved (enamel-dentine junction)
  • Able and willing to observe good oral hygiene throughout the study
  • Age ≥ 18 years and ≤ 65 years
  • Willing and able to attend the on-study visits
  • Willing and able to understand all study-related procedures
  • Written informed consent before participation in the study

Exclusion criteria

  • The two study test lesions are located on adjacent teeth
  • Fluoride varnish application < 3 months prior to study treatment
  • Tooth with numerous carious lesions
  • Evidence of tooth erosion
  • History of head and neck illnesses (e.g. head/neck cancer)
  • Any pathology or concomitant medication affecting salivary flow or dry mouth
  • Any metabolic disorders affecting bone turnover
  • Patient suffers from diabetes
  • Concurrent participation in another clinical trial
  • Women who are breast-feeding, pregnant or who plan a pregnancy during the study
  • Women of childbearing potential who declare being unwilling or unable to practice contraception such as hormonal contraceptives, sexual abstinence or intercourse with a vasectomised partner

Treatment and study plan

Curodont Repair

Device

Self-assembling peptide, biomimetic re-mineralisation

Application on Day 0 and Day 360

Other names: P11-4

Fluoride

Device

Application on Day 0, Day 180, Day 360, Day 540

Other names: Duraphat

Primary outcomes

  1. Opaqueness on X-Ray

    Time frame: Day 360

    The primary efficacy outcome is the difference of the change in the opaqueness of the carious lesion on the x-ray picture from Day 0 to Day 365 between test and control group.

Secondary outcomes

  1. Additional benefit of a second Curodont Repair application

    Time frame: Day 720

    The secondary efficacy outcome is the difference of the change in the opaqueness of the carious lesion on the x-ray picture from Day 360 to Day 720 between test and control group.

Sponsors and collaborators

Lead sponsor

Credentis AG

Industry

Registry information

Official study title

Effect of Curodont™ Repair in Patients With Early Approximal Carious Lesions: A Mono-centre, Controlled, Single-blinded, Randomised, Split-mouth, Post-marketing Study

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Apr 2, 2014
Registry last updated
Jul 18, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.